ResearcherSecond Military Medical UniversityActive in the last 2 years
Lingyu Zhu
Matched on ORCID iD 0000-0001-9242-5863; OpenAlex author ID A5086114545. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2023: 4 papers · 2024: none · 2025: 2 papers · 2026: 2 papers
Papers 8
- The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2026.218252↗
- Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy" [Cancer Lett. (202… Co-author DOI 10.1016/j.canlet.2026.218298↗
- Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Co-author DOI 10.1016/j.surg.2024.109045↗
- Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
- Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
- A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
- Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma First author DOI 10.21203/rs.3.rs-2856912/v1↗
- [Establishment of the quality assessment system for pancreatic cancer surgery: from "single complication assessment" to "textbook outcome"]. Co-author DOI 10.3760/cma.j.cn112139-20230308-00097↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaoyi Yin · 7 shared papers, 2023–2026 · strength 1.24
- Paper Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac a… DOI 10.1016/j.surg.2024.109045↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Gang Jin · 6 shared papers, 2023–2026 · strength 1.18
- Paper [Establishment of the quality assessment system for pancreatic cancer surgery: from "single complication assessment" to… DOI 10.3760/cma.j.cn112139-20230308-00097↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Shiwei Guo · 6 shared papers, 2023–2025 · strength 1.16
- Paper [Establishment of the quality assessment system for pancreatic cancer surgery: from "single complication assessment" to… DOI 10.3760/cma.j.cn112139-20230308-00097↗
- Paper Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac a… DOI 10.1016/j.surg.2024.109045↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Kailian Zheng · 6 shared papers, 2023–2026 · strength 1.08
- Paper Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac a… DOI 10.1016/j.surg.2024.109045↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Xiaohan Shi · 6 shared papers, 2023–2026 · strength 1.05
- Paper Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac a… DOI 10.1016/j.surg.2024.109045↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Suizhi Gao · 5 shared papers, 2023–2025 · strength 0.85
- Paper Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac a… DOI 10.1016/j.surg.2024.109045↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Paper A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-023-11181-x↗
- Xiongfei Xu · 4 shared papers, 2023–2026 · strength 0.71
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Yunguang Li · 3 shared papers, 2025–2026 · strength 0.58
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Shuo Shen · 3 shared papers, 2023 · strength 0.45
- Paper A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-023-11181-x↗
- Paper Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resect… DOI 10.21203/rs.3.rs-2856912/v1↗
- Paper Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. DOI 10.1093/bjs/znac457↗
- Guoxiao Zhang · 3 shared papers, 2023 · strength 0.45
- Paper A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. DOI 10.1186/s12885-023-11181-x↗
- Paper Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resect… DOI 10.21203/rs.3.rs-2856912/v1↗
- Paper Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. DOI 10.1093/bjs/znac457↗
- Yehan Zhang · 2 shared papers, 2026 · strength 0.39
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Meilong Shi · 2 shared papers, 2026 · strength 0.39
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Gang Y Jin · 2 shared papers, 2023–2025 · strength 0.37
- Bo Li · 2 shared papers, 2023 · strength 0.29
- Jian Wang · 2 shared papers, 2023 · strength 0.29
- Zhendong Fu · 1 shared paper, 2025 · strength 0.21
- Meilong Shi · 1 shared paper, 2025 · strength 0.21
- Huan Wang · 1 shared paper, 2026 · strength 0.20
- Huan Wang · 1 shared paper, 2026 · strength 0.20
- Bo Li · 1 shared paper, 2025 · strength 0.19
- Dong Gao · 1 shared paper, 2025 · strength 0.19
- Eric Tran · 1 shared paper, 2025 · strength 0.19
- Hui Jiang · 1 shared paper, 2023 · strength 0.16
- Bin Song · 1 shared paper, 2023 · strength 0.13
- Zhuo Shao · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.